Cargando…
The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod
Almost all drugs approved for use in humans possess potentially beneficial ‘off-target’ effects in addition to their principal activity. In some cases this has allowed for the relatively rapid repurposing of drugs for other indications. In this review we focus on the potential for re-purposing FTY72...
Autores principales: | Patmanathan, Sathya Narayanan, Yap, Lee Fah, Murray, Paul G, Paterson, Ian C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4594675/ https://www.ncbi.nlm.nih.gov/pubmed/26171944 http://dx.doi.org/10.1111/jcmm.12635 |
Ejemplares similares
-
The emerging role of FTY720 (Fingolimod) in cancer treatment
por: White, Christopher, et al.
Publicado: (2016) -
Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011) -
Protective role of fingolimod (FTY720) in rats subjected to subarachnoid hemorrhage
por: Xu, Hao-Liang, et al.
Publicado: (2015) -
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
por: Sharma, Sushil, et al.
Publicado: (2011) -
The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage
por: Stradner, Martin H, et al.
Publicado: (2011)